Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.

Ain Shams University

Status: Active, not recruiting

Conditions: Anesthesia

Treatments: Other: Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.; Drug: Pericapsular nerve group (PENG) block

Study type: Interventional

Funder types: Other

Identifiers

NCT06916000

FMASU MS428/2024

Details and patient eligibility

About

to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties

Full description

PENG block is a novel block described by Giron-Arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance So currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system Our primary outcome to be studied is pain assessment via Numer Rating Scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age group: 18 years and older.
• ASA classification I to III.
• BMI : 18-35 .
• Gender: both sex

Exclusion criteria

• Patient refusal.
• Patients on long-term pain medications.
• History of allergic reactions to local anesthetics
• Patients who had mental illness or uncooperative patients.
• BMI > 35 .
• Patients having coagulopathies or on anticoagulant or antiplatelet therapy.
• Severe cardiopulmonary disease
• ASA IV or more
• Diabetic or other neuropathies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

50 participants in 2 patient groups

PENG block group (25 particiants)

Active Comparator group

Description:

For postoperative pain management, all patients of this arm will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango. In addition, multimodal analgesia will be given including IV paracetamol 1000 mg BID and oral celecoxib tablet 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as demand dose and when the NRS pain score was equal to or greater than 4 points.

Treatment:

Drug: Pericapsular nerve group (PENG) block

Group C: control group (25 participants)

Experimental group

Description:

Patients will receive only other multimodal analgesics

Treatment:

Other: Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.